AXNX:NSD-Axonics Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 47.33

Change

+0.04 (+0.08)%

Market Cap

USD 2.23B

Volume

0.40M

Avg Analyst Target

USD 69.20 (+46.21%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Axonics Inc (AXNX) Stock Analysis:
Based on the Axonics Inc stock forecasts from 6 analysts, the average analyst target price for Axonics Inc is USD 69.20 over the next 12 months. Axonics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Axonics Inc is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, Axonics Inc’s stock price was USD 47.33. Axonics Inc’s stock price has changed by +19.82% over the past week, -25.83% over the past month and -12.40% over the last year.

About

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

-10.14 (-3.03%)

USD32.85B 171.14 77.12
ALGN Align Technology Inc

-1.32 (-0.48%)

USD21.71B 31.02 18.18
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
PODD Insulet Corporation

-2.15 (-1.08%)

USD13.80B 829.42 84.91
ABMD Abiomed Inc

-0.37 (-0.15%)

USD11.58B 85.29 42.14
BRKR Bruker Corporation

-0.66 (-1.10%)

USD8.99B 33.27 17.75
SWAV ShockWave Medical Inc

+1.24 (+0.76%)

USD5.81B N/A 138.45
IART Integra LifeSciences Holdings ..

+0.39 (+0.66%)

USD4.93B 32.22 16.98
TNDM Tandem Diabetes Care Inc

-1.89 (-2.56%)

USD4.72B 307.71 186.72
IRTC iRhythm Technologies Inc

-6.04 (-4.34%)

USD3.93B N/A N/A

ETFs Containing AXNX

Symbol Name Weight Mer Price(Change) Market Cap
UNIC:LSE Lyxor Index Fund - Lyxor .. 0.00 % 0.45 %

-0.08 (-0.67%)

N/A
DRUP:XETRA Lyxor Index Fund - Lyxor .. 0.00 % 0.45 %

-0.07 (-0.66%)

USD0.17B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.48% 82% B- 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.48% 82% B- 56% F
Trailing 12 Months  
Capital Gain -13.01% 80% B- 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.01% 80% B- 56% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 36.87% 66% D 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.87% 66% D 84% B
Risk Return Profile  
Volatility (Standard Deviation) 43.03% 71% C- 35% F
Risk Adjusted Return 85.68% 97% A+ 94% A
Market Capitalization 2.23B 89% B+ 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.50 23% F 17% F
Price / Cash Flow Ratio -47.05 92% A- 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -20.80% 58% F 35% F
Return on Invested Capital -18.36% 50% F 33% F
Return on Assets -9.46% 58% F 31% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 10.10 14% F 10% F
Short Percent 9.18% 11% F 19% F
Beta 0.35 87% B+ 88% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector